poisar

Stock

Corbus Pharmaceuticals Holdings, Inc. CRBP

$10.09+0.10%

Overview

CRBP market data

Price History

CRBP price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$3.64
Diluted earnings per share over the trailing twelve months.
Beta
2.57
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-2,838.7%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$7.12 – $20.56
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $185.1M · P/B 0.97 · P/S 119.42.

Company News

10 captured
Corbus Pharmaceuticals Enters Open Market Sale Agreement With Jefferies; Co. To Offer And Sell Common Stock Up To $127.50M Through JefferiesBenzinga · Aug 7, 2026, 8:46 PM
Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $48Benzinga · Aug 7, 2026, 1:58 PM
HC Wainwright & Co. Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $35Benzinga · Aug 7, 2026, 1:09 PM
Corbus Pharmaceuticals Q2 EPS $(1.81) Misses $(1.26) EstimateBenzinga · Aug 6, 2026, 12:32 PM
8-K filing — Corbus Pharmaceuticals Holdings, Inc. (CRBP)SEC EDGAR · Aug 6, 2026, 12:15 PM
Corbus Pharmaceuticals' Last Participant Completes Last Clinical Visit In Its CANYON-1 Phase 1b Clinical Study Of CRB-913 To Treat ObesityBenzinga · Aug 4, 2026, 12:33 PM
Corbus Pharmaceuticals Receives FDA Clearance To Start Its TEMPO-1 Registrational StudyOf CRB-701, A Nectin-4 Targeted Antibody Drug Conjugate In Second-Line Oropharyngeal Squamous Cell CarcinomaBenzinga · Jul 28, 2026, 12:03 PM
Mizuho Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $34Benzinga · Jun 23, 2026, 3:10 PM
Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $52Benzinga · Jun 17, 2026, 1:35 PM
Wedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $30Benzinga · May 27, 2026, 1:35 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock